Pfizer Inc. $PFE Shares Bought by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 642.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 318,584 shares of the biopharmaceutical company’s stock after buying an additional 275,671 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Pfizer were worth $8,946,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Horizon Financial Services LLC raised its stake in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the fourth quarter valued at approximately $26,000. YANKCOM Partnership bought a new position in shares of Pfizer during the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Abound Financial LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Citigroup boosted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. Finally, Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.82.

Pfizer Stock Performance

Shares of PFE stock opened at $24.29 on Friday. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market capitalization of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35. The business has a 50 day simple moving average of $25.68 and a 200 day simple moving average of $26.24.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio is presently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.